Bicycle Therapeutics (NASDAQ:BCYC) CEO Sells $70,210.00 in Stock

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) CEO Kevin Lee sold 10,325 shares of the stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $6.80, for a total value of $70,210.00. Following the completion of the transaction, the chief executive officer directly owned 629,985 shares in the company, valued at approximately $4,283,898. This represents a 1.61% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Kevin Lee also recently made the following trade(s):

• On Monday, January 5th, Kevin Lee sold 10,989 shares of Bicycle Therapeutics stock. The stock was sold at an average price of $6.46, for a total value of $70,988.94.

Bicycle Therapeutics Trading Down 3.5%

Shares of Bicycle Therapeutics stock opened at $6.63 on Friday. The firm has a market capitalization of $459.91 million, a PE ratio of -1.83 and a beta of 1.52. Bicycle Therapeutics PLC Sponsored ADR has a 12 month low of $6.03 and a 12 month high of $15.43. The business’s 50-day moving average price is $6.90 and its 200-day moving average price is $7.41.

Bicycle Therapeutics (NASDAQ:BCYC) last released its earnings results on Thursday, October 30th. The company reported ($0.85) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.09) by $0.24. Bicycle Therapeutics had a negative return on equity of 36.05% and a negative net margin of 884.51%.The company had revenue of $11.73 million during the quarter, compared to the consensus estimate of $8.25 million. As a group, analysts predict that Bicycle Therapeutics PLC Sponsored ADR will post -3.06 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Armistice Capital LLC lifted its holdings in Bicycle Therapeutics by 6.4% in the 3rd quarter. Armistice Capital LLC now owns 2,978,000 shares of the company’s stock worth $23,050,000 after buying an additional 178,000 shares during the period. Long Focus Capital Management LLC lifted its stake in Bicycle Therapeutics by 7.7% in the third quarter. Long Focus Capital Management LLC now owns 1,418,695 shares of the company’s stock worth $10,981,000 after acquiring an additional 101,402 shares during the period. Moore Capital Management LP boosted its holdings in Bicycle Therapeutics by 66.7% in the third quarter. Moore Capital Management LP now owns 125,000 shares of the company’s stock valued at $968,000 after acquiring an additional 50,000 shares in the last quarter. Citadel Advisors LLC increased its position in Bicycle Therapeutics by 20.3% during the 3rd quarter. Citadel Advisors LLC now owns 189,027 shares of the company’s stock valued at $1,463,000 after purchasing an additional 31,860 shares during the period. Finally, Ameriprise Financial Inc. increased its position in Bicycle Therapeutics by 21.7% during the 3rd quarter. Ameriprise Financial Inc. now owns 14,972 shares of the company’s stock valued at $116,000 after purchasing an additional 2,668 shares during the period. Institutional investors own 86.15% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on BCYC shares. Truist Financial initiated coverage on shares of Bicycle Therapeutics in a research report on Monday, November 24th. They issued a “hold” rating and a $10.00 target price on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bicycle Therapeutics in a report on Monday, December 22nd. JMP Securities set a $12.00 target price on Bicycle Therapeutics in a report on Friday, October 31st. Citigroup restated an “outperform” rating on shares of Bicycle Therapeutics in a research report on Friday, October 31st. Finally, Citizens Jmp boosted their price objective on Bicycle Therapeutics from $10.00 to $12.00 and gave the company a “market outperform” rating in a research report on Friday, October 31st. Seven research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $19.73.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.